Abstract
There is limited knowledge of the use of direct acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) in sub-Saharan Africa. We prospectively evaluated individuals infected with HCV genotypes 1 to 5 in Addis Ababa, Ethiopia. Liver fibrosis was assessed by AST-platelet ratio index score and cirrhosis by imaging and laboratory values. All 164 individuals completed treatment. The majority of patients had genotype 4 (76%), and 19% of participants showed evidence of cirrhosis. Sustained virologic response (SVR) across all genotypes was 98.8%. In those with cirrhosis, SVR was 93.5% and in non-cirrhotics 100%. Our study demonstrates broad genotype successful treatment of HCV with DAAs in sub-Saharan Africa, demonstrating the feasibility of HCV elimination in resource-limited settings.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2083-2084 |
| Number of pages | 2 |
| Journal | American Journal of Tropical Medicine and Hygiene |
| Volume | 103 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2020 |
Bibliographical note
Funding Information:Financial support: This study was supported by Harold Amos Medical Faculty Development Award (AMFDP), NIH-NCI R21 CA215883-01A1, and University of Minnesota Center for Global Health and Social Responsibility Global Health Seed Award to J. D. D.
Publisher Copyright:
Copyright © 2020 by The American Society of Tropical Medicine and Hygiene
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Treatment of hepatitis C genotypes 1 to 5 in sub-saharan Africa using direct-acting antivirals'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS